SEC 13F Intelligence

Ghost Tree Capital, LLC / MLTX

Ghost Tree Capital, LLC’s Moonlake Immunotherapeutics Position

Does Ghost Tree Capital, LLC own Moonlake Immunotherapeutics (MLTX)? Yes — 128.4K shares worth $6M (+1.96% of its 13F portfolio) as of Q3 2024, down from 300.0K shares the prior filed quarter.

Position Value
$6M
Q3 2024
Shares
128.4K
% of Portfolio
+1.96%
Quarters Held
9
currently held

Position History MLTX

Reported value by quarter
Q2 ’22: $2MQ2 ’22Q3 ’22: $2MQ1 ’23: $4MQ1 ’23Q2 ’23: $17MQ3 ’23: $19MQ3 ’23Q4 ’23: $5MQ1 ’24: $15MQ1 ’24Q2 ’24: $13MQ3 ’24: $6MQ3 ’24filingsflow.com
QuarterSharesValue% of Portfolio
Q3 2024128.4K$6M+1.96%
Q2 2024300.0K$13M+4.13%
Q1 2024300.0K$15M+4.17%
Q4 202380.0K$5M+1.58%
Q3 2023330.0K$19M+6.19%
Q2 2023330.0K$17M+5.56%
Q1 2023195.0K$4M+1.23%
Q3 2022300.0K$2M+0.65%
Q2 2022300.0K$2M+0.82%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Ghost Tree Capital, LLC’s full portfolio or all institutional holders of MLTX.